FDA Moves to Reevaluate Several Peptides American Med Spa Association The FDA's Current Position on Peptides Explained Holt Law The trend of unproven peptides is spreading through influencers and RFK Jr. allies CNN The biggest peptide story of 2026 may not be a new study. It may be the FDA review calendar. BPC 157, TB 500, MOTS c, Semax, and other peptides are headed into FDA advisory review